Takeda Pharmaceutical (NYSE:TAK) Issues FY 2024 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 3.060-3.060 for the period. The company issued revenue guidance of $30.1 billion-$30.1 billion.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK opened at $13.89 on Thursday. Takeda Pharmaceutical has a 1 year low of $12.57 and a 1 year high of $15.08. The stock has a market capitalization of $44.20 billion, a price-to-earnings ratio of 25.25, a price-to-earnings-growth ratio of 0.26 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. The company’s 50 day simple moving average is $14.51 and its 200 day simple moving average is $13.78.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. The company had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. As a group, research analysts predict that Takeda Pharmaceutical will post 1.58 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.